JPRN-UMIN000007801已完成1 期
Phase I/II clinical trial of HLA-A24 restricted epitope peptide cocktail therapy with UFT+LV for patients with advanced metastatic colorectal cancer. - Peptide vaccine therapy with UFT+LV for patients with advanced metastatic colorectal cancer.
Kinki University School of Medicine0 个研究点目标入组 30 人开始时间: 2012年4月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Pregnant Lactation Prognosis >= 3 months Active infectious disease Systemic use of steroid hormones or immunosuppressive drugs. Others (Doctors judges)
研究者
相似试验
已完成
1 期
Phase I clinical trial of HLA-A*2402 restricted epitope peptide cocktail therapy with S-1 for patients with unresectable advanced metastatic pancreatic cancer.pancreatic cancerJPRN-UMIN000009881Sapporo Medical University9
招募中
2 期
Phase II clinical study of HLA-A*2402-restricted survivin-derived peptide vaccine therapy for patients with recurrent non-muscle-invasive bladder cancerbladder cancerJPRN-UMIN000005819Sapporo Medical University20
已完成
1 期
Cancer vaccine therapy with HLA-A24 restricted epitope peptide cocktail for patients with advanced metastatic colorectal cancer. Phase I/II clinical trial.Advanced metastatic colorectal cancersJPRN-UMIN000004959Tokai University School of Medicine30
招募中
1 期
Cancer vaccine therapy with HLA-A24 restricted epitope peptide cocktail for patients with advanced metastatic colorectal cancer. Phase I/II clinical trial.Advanced metastatic colorectal cancersJPRN-UMIN000006312Kinki University School of Medicine Department of Surgery30
已完成
1 期
Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide Combined with IFA and IFN-alpha for Patients with Urothelial Cancer (Phase I clinical study)JPRN-UMIN000005859Department of Urology, Sapporo Medical University School of Medicine15